Trump signals tariff plans, Fed chair candidates, China deal progress
Adam C. Vandervoort, the Chief Legal Officer and Secretary of Teladoc Health, Inc. (NYSE:TDOC), recently reported a sale of company stock. According to a filing with the Securities and Exchange Commission, Vandervoort sold 3,935 shares of Teladoc common stock on March 3, 2025. The shares were sold at an average price of $9.684, amounting to a total transaction value of $38,106. The sale comes amid a challenging period for Teladoc’s stock, which has declined over 15% in the past week, though InvestingPro analysis suggests the stock is currently undervalued.
Additionally, Vandervoort executed multiple transactions involving the conversion of restricted and performance stock units into common stock. On February 28, 2025, he converted 1,881 restricted stock units, 4,418 restricted stock units, and 1,505 performance stock units into common stock. These conversions were conducted at no cost, as the units convert to Teladoc common stock on a one-for-one basis. The company, currently valued at $1.6 billion, maintains a "GOOD" Financial Health score according to InvestingPro’s comprehensive analysis, which includes over 30 key financial metrics and exclusive insights.
Following these transactions, Vandervoort’s direct ownership of Teladoc Health stock stands at 53,919 shares. Despite recent volatility, the stock has shown resilience with a 26.75% gain over the past six months.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings with a revenue of $640.5 million, slightly surpassing the forecast of $638.5 million. However, the company reported an earnings per share (EPS) of -$0.28, missing the expected -$0.23, contributing to investor concerns. The full-year revenue for 2024 was $2.6 billion, marking a 1% decrease from the previous year. Analysts at Stifel maintained a Hold rating on Teladoc shares, citing the company’s guidance for 2025, which fell below market expectations but aligned with their projections. Needham also reiterated a Hold rating, noting challenges such as the loss of a large client and currency exchange headwinds impacting the company’s outlook for 2025. Teladoc’s BetterHelp division saw a sequential increase in average paying users during the fourth quarter, although the company continues to seek stabilization in this segment. The new CEO is focusing on initiatives to stabilize customer acquisition costs and expand the international business, which has shown success.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.